Cannabix Looks to Solve Roadside THC Testing Issues
Ryan Allway
April 12th, 2017
News, Top News
There is little question that marijuana impairment is causing issues as recreational and medical marijuana legalization sweeps the nation, but regulators and medical professionals disagree on the best ways to design and implement driving laws. This week we learned that the Canadian Government is working to introduce legislation prior to April 20th, that would legalize and regulate marijuana in Canada. The good news is that some companies are working on roadside breathalyzer solutions designed to ease these concerns by providing an instant look at THC concentrations without drawing blood.
In this article, we will take a look at Cannabix Technologies Inc.’s (CSE: BLO) (OTC: BLOZF) recent progress in developing a roadside THC breathalyzer.
Conventional Testing Issues
There’s no question that marijuana impairment is causing issues on the nation’s roadways. The NHTSA estimates that up to one-in-ten weekend nighttime drivers in the U.S. may have THC in their bodies, while the IIHS projects that THC’s effects double a driver’s crash risk. Colorado police found that marijuana-involved road fatalities have doubled in the state following recreational legalization – a trend that could spread throughout the country.
Despite acknowledging the problem, there is widespread disagreement on the part of both regulators and medical professionals about how to test for marijuana impairment. Existing detection methods for cannabis use, including those based on blood, urine, and oral fluid (saliva) can detect THC and its metabolites many days or even weeks after the last cannabis intake, making it difficult, if not impossible, to determine recent cannabis intake accurately.
Colorado and Washington State established so-called per se limits that limit blood concentrations to less than 5ng/mL of THC, while other states have zero-tolerance rules or no rules for driving impairment at all. Research must still conduct fundamental research looking at the correlation between the presence of THC and actual impairment, while taking into account the significant differences between heavy regular users and rare new users.
New Testing Confirms Efficacy
The ideal device for roadside testing would be a breathalyzer since it provides immediate feedback and is already in use by law enforcement and is understood by the public as a non-invasive tool. Unfortunately, police are limited to invasive blood tests or ineffective mouth swabs at the moment as breathalyzer technology is perfected. The good news is companies like Cannabix Technologies are drawing closer to developing a functional device that’s ready for live use.
“The high resolving power of the FAIMS device with its capability for real time detection of THC and its metabolic breakdown products will aid in establishing key metrics for measuring in-vivo THC metabolism and should permit detection capabilities similar to that of blood tests. The current human testing on the FAIMS based Cannabix Marijuana Breathalyzer has shown impressive results thus far,” said Cannabix Technologies’ Dr. Raj Attariwala.
The company recently announced that preliminary testing on human subjects showed that its Beta prototype breathalyzer is capable of detecting THC in real-time in subjects that smoked THC cigarettes. In addition to detecting THC, the device detected 11-hydroxy-delta-9-tetrahydrocannabinol, delta-9-carboxy-tetrahydrocannabinol, and three other cannabinoids related to cannabigerol that could be valuable to law enforcement.
The company plans to further test its Beta and Beta 2.0 prototypes over the coming weeks, where it will calibrate decay signal intensities with a refined breath collection component. The goal is to enable the breakthrough device to zero in on impairment with ‘recency of use’ like no other device on the market. With a first-mover advantage, the company could rapidly build market share in both the United States and Canada and globally.
Looking Ahead
Cannabix Technologies Inc. (CSE: BLO) (OTC: BLOZF) represents a compelling opportunity in the cannabis industry as it develops its breakthrough THC breathalyzer. With on going testing underway, the company has become a leader in this emerging space. Investors may want to take a look at the stock as it moves closer to commercialization over the coming quarters.
For more information, visit the company’s website or CannabisFN’s company profile.
This article was published by CFN Enterprises Inc. (OTCQB: CNFN), owner and operator of CFN Media, the industry’s leading agency and digital financial media network dedicated to the burgeoning CBD and legal cannabis industries. Call +1 (833) 420-CNFN for more information.
About Ryan Allway
Mr. Allway has over a decade of experience in the financial markets as both a private investor and financial journalist. He has been actively involved in the cannabis industry since its inception, covering public and private companies.
Search CannabisFN
Press Coverage
Psychedelics Index
Top Videos
Matthew Nordgren is an ambitious executive, dedicated philanthropist, and accomplished athlete who brings a unique passion to creating strategic alliances. He has breadth and depth of experience in finance, corporate development, and capital sourcing, as well as in building highly motivated teams of skilled professionals. In 2005, Mr. Nordgren received his education at the University […]
Tom Zuber is Zuber Lawler & Del Duca’s Managing Partner. He has a degree with highest honors in biomedical engineering and has advised some of the most iconic companies in the world on their patent and trademark portfolios. He is at the cutting edge of cannabis patent and trademark law. He holds degrees from Harvard University and Columbia Law […]
Headquartered in Lakewood, Colo., STWC Holdings is a complete ecosystem of entities and services that support the burgeoning cannabis industry.
Revive Therapeutics’ cannabinoid pharmaceutical portfolio focuses on rare inflammatory areas such as liver disease.
Network Partners
About CFN Media Group
CFN Enterprises Inc. (OTCQB: CNFN) owns and operates CFN Media Group, the premier agency and financial media network reaching executives, entrepreneurs and consumers worldwide. Through its proprietary content creation, video library, and distribution via www.CannabisFN.com, CFN has built an extensive database of cannabis interest, assisting many of the world’s largest cannabis firms and CBD brands to build awareness and thrive. For more information, please visit www.cfnenterprisesinc.com.
Disclaimer: Matters discussed on this website contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. CFN Media Group, which owns CannabisFN, is not registered with any financial or securities regulatory authority and does not provide nor claims to provide investment advice or recommendations to readers of this release. CFN Media Group, which owns CannabisFN, may from time-to-time have a position in the securities mentioned herein and will increase or decrease such positions without notice. The Information contains forward-looking statements, i.e. statements or discussions that constitute predictions, expectations, beliefs, plans, estimates, or projections as indicated by such words as "expects", "will", "anticipates", and "estimates"; therefore, you should proceed with extreme caution in relying upon such statements and conduct a full investigation of the Information and the Profiled Issuer as well as any such forward-looking statements. Any forward looking statements we make in the Information are limited to the time period in which they are made, and we do not undertake to update forward looking statements that may change at any time; The Information is presented only as a brief "snapshot" of the Profiled Issuer and should only be used, at most, and if at all, as a starting point for you to conduct a thorough investigation of the Profiled Issuer and its securities and to consult your financial, legal or other adviser(s) and avail yourself of the filings and information that may be accessed at www.sec.gov, www.pinksheets.com, www.otcmarkets.com or other electronic sources, including: (a) reviewing SEC periodic reports (Forms 10-Q and 10-K), reports of material events (Form 8-K), insider reports (Forms 3, 4, 5 and Schedule 13D); (b) reviewing Information and Disclosure Statements and unaudited financial reports filed with the Pink Sheets or www.otcmarkets.com; (c) obtaining and reviewing publicly available information contained in commonlyknown search engines such as Google; and (d) consulting investment guides at www.sec.gov and www.finra.com. You should always be cognizant that the Profiled Issuers may not be current in their reporting obligations with the SEC and OTCMarkets and/or have negative signs at www.otcmarkets.com (See section below titled "Risks Related to the Profiled Issuers, which provides additional information pertaining thereto). For making specific investment decisions, readers should seek their own advice and that of their own professional advisers. CFN Media Group, which owns CannabisFN, may be compensated for its Services in the form of cash-based and/or equity-based compensation in the companies it writes about, or a combination of the two. For full disclosure, please visit: https://www.cannabisfn.com/legal-disclaimer/. A short time after we acquire the securities of the foregoing company, we may publish the (favorable) information about the issuer referenced above advising others, including you, to purchase; and while doing so, we may sell the securities we acquired. In addition, a third-party shareholder compensating us may sell his or her shares of the issuer while we are publishing favorable information about the issuer. Except for the historical information presented herein, matters discussed in this article contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. CFN Media Group, which owns CannabisFN, is not registered with any financial or securities regulatory authority, and does not provide nor claims to provide investment advice or recommendations to readers of this release. CFN Media Group, which owns CannabisFN, may from time to time have a position in the securities mentioned herein and will increase or decrease such positions without notice. For making specific investment decisions, readers should seek their own advice and that of their own professional advisers. CFN Media Group, which owns CannabisFN, may be compensated for its Services in the form of cash-based and/or equity- based compensation in the companies it writes about, or a combination of the two. For full disclosure please visit: https://www.cannabisfn.com/legal-disclaimer/.
Copyright © Accelerize Inc. · All Rights Reserved · Privacy Policy · Legal Disclaimer
